开云app官网登录入口网页版-官方正版

#Tucatinib#

8篇内容 | 1013人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1536979, encodeId=554015369e9b8, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=Ann Oncol：Tucatinib（图卡替尼）或安慰剂联合曲妥珠单抗+卡培他滨治疗经治晚期HER2+乳腺癌患者的疗效, objectType=article, longId=295100, objectId=fc8c295100d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc8c295100d4, replyNumber=0, likeNumber=72, createdTime=2022-02-05, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc8c295100d4, moduleTitle=Ann Oncol：Tucatinib（图卡替尼）或安慰剂联合曲妥珠单抗+卡培他滨治疗经治晚期HER2+乳腺癌患者的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fc8c295100d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536978, encodeId=33d215369e8d1, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=Clin Cancer Res：Tucatinib获批治疗晚期HER2阳性乳腺癌, objectType=article, longId=202248, objectId=6763202248e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6763202248e2, replyNumber=0, likeNumber=71, createdTime=2020-10-19, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6763202248e2, moduleTitle=Clin Cancer Res：Tucatinib获批治疗晚期HER2阳性乳腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6763202248e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536977, encodeId=4ad215369e77a, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, objectType=article, longId=199343, objectId=af9d1993432d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9d1993432d, replyNumber=0, likeNumber=50, createdTime=2020-08-14, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9d1993432d, moduleTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=af9d1993432d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536976, encodeId=723515369e63a, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, objectType=article, longId=187241, objectId=618618e241e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618618e241e2, replyNumber=0, likeNumber=49, createdTime=2020-02-04, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618618e241e2, moduleTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=618618e241e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536975, encodeId=559215369e503, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, objectType=article, longId=184670, objectId=4c281846e069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c281846e069, replyNumber=0, likeNumber=66, createdTime=2019-12-14, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c281846e069, moduleTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4c281846e069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536974, encodeId=268015369e4e4, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功, objectType=article, longId=181705, objectId=c214181e05e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c214181e05e3, replyNumber=0, likeNumber=47, createdTime=2019-10-23, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c214181e05e3, moduleTitle=Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c214181e05e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536973, encodeId=fcbb15369e39e, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, objectType=article, longId=139112, objectId=33c3139112e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33c3139112e3, replyNumber=0, likeNumber=54, createdTime=2018-05-27, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33c3139112e3, moduleTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=33c3139112e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536972, encodeId=868515369e284, content=<a href='/topic/show?id=2ca71e927c5' target=_blank style='color:#2F92EE;'>#Tucatinib#</a>, objectTitle=ESMO 2016：Tucatinib可有效治疗乳腺癌皮肤转移患者, objectType=article, longId=80187, objectId=cbf48018e22, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf48018e22, replyNumber=0, likeNumber=60, createdTime=2016-10-18, rootId=0, userName=hxq78320, userId=7c1612763464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf48018e22, moduleTitle=ESMO 2016：Tucatinib可有效治疗乳腺癌皮肤转移患者, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cbf48018e22)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Tucatinib

2020-05-29

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

Ann Oncol：Tucatinib（图卡替尼）或安慰剂联合曲妥珠单抗+卡培他滨治疗经治晚期HER2+乳腺癌患者的疗效

2022-02-05

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

Clin Cancer Res：Tucatinib获批治疗晚期HER2阳性乳腺癌

2020-10-19

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌

2020-08-14

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请

2020-02-04

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌

2019-12-14

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功

2019-10-23

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果

2018-05-27

hxq78320 (审核中...)

前往app查看评论内容

#Tucatinib#

ESMO 2016：Tucatinib可有效治疗乳腺癌皮肤转移患者

2016-10-18

科室
- - 订阅+
  - 更多科室
工具
服务